drugset / Trial / NCT05200143
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Phase 2
Terminated
4 enrolled
Providence Health & Services
Bristol-Myers Squibb · collabExelixis · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.
Timeline
- Start
- 2022-06-08
- Primary completion
- 2023-09-11
- Completion
- 2024-07-23
Outcome
Outcome not reported
Stopped: “Withdrawn support from BMS.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 40 mg | Oral |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |
Indications
No indication recorded.